The rationale for targeted therapies and stereotactic radiosurgery in the treatment of brain metastases Journal Article


Authors: Moraes, F. Y.; Taunk, N. K.; Marta, G. N.; Suh, J. H.; Yamada, Y.
Article Title: The rationale for targeted therapies and stereotactic radiosurgery in the treatment of brain metastases
Abstract: Brain metastases are the most common intracranial malignancy. Many approaches, including radiation therapy, surgery, and cytotoxic chemotherapy, have been used to treat patients with brain metastases depending on the patient’s disease burden and symptoms. However, stereotactic surgery (SRS) has revolutionized local treatment of brain metastases. Likewise, targeted therapies, including small-molecule inhibitors and monoclonal antibodies that target cancer cell metabolism or angiogenesis, have transformed managing systemic disease. Prospective data on combining these treatments for synergistic effect are limited, but early data show favorable safety and efficacy profiles. The combination of SRS and targeted therapy will further individualize treatment, potentially obviating the need for cytotoxic chemotherapy or whole-brain radiation.There is a great need to pursue research into these exciting modalities and novel combinations to further improve the treatment of patients with brain metastases.This article discusses reported and ongoing clinical trials assessing the safety and efficacy of targeted therapy during SRS. © AlphaMed Press 2016.
Keywords: brain metastasis; targeted therapy; stereotactic radiosurgery
Journal Title: The Oncologist
Volume: 21
Issue: 2
ISSN: 1083-7159
Publisher: Oxford University Press  
Date Published: 2016-02-01
Start Page: 244
End Page: 251
Language: English
DOI: 10.1634/theoncologist.2015-0293
PROVIDER: scopus
PMCID: PMC4746085
PUBMED: 26764249
DOI/URL:
Notes: Article -- Export Date: 3 March 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Yoshiya Yamada
    479 Yamada
  2. Neil Taunk
    31 Taunk